Hunting illusive signs of natural selection

September 08, 2004

The move from Africa into the rest of the world provided environmental challenges that are visible in our genetic makeup if one looks very carefully, according to a team of biologists and anthropologists.

"We want to understand where and how natural selection occurs," says Dr. Mark Shriver, associate professor of anthropology at Penn State. "However, most changes in genes are neutral and caused by the demographic history of the population."

Neutral demographic changes in populations occur because separated populations drift apart, decimated populations expand from smaller gene pools, and populations mix with each other.

Most individual mutations that occur in the genetic code are neutral or benign. These changes have no impact on the survival fitness of the individual and remain or disappear by chance. Some mutations destroy the ability of that part of the code to do its job, and the individual does not survive or reproduce relative to other members of the population. These individuals are generally selected out of the population because they are less fit. Other mutations accidentally provide a change that makes individuals more fit for their environment and gives them an advantage. These individuals are more fit and reproduce more, increasing the prevalence of that particular trait in the population.

"To identify genes that were naturally selected, it is important to know the demographic history of the populations being studied," says Shriver.

Researchers at Fred Hutchinson Cancer Research Center in Seattle created demographic models of possible population histories and applied them to genetic information from two populations - one African-American and the other European-American - sequenced at the University of Washington, Seattle. The four models represented populations that expanded exponentially, rapidly decreased to a small population size causing a bottleneck and then increased, where separated with only small amounts of interbreeding and split completely.

The researchers, who included Shriver; Joshua M. Akey, Fred Hutchinson Cancer Research Center; Mark J. Rieder, Christopher S. Carlson and Deborah A. Nickerson, University of Washington; and Leonid Kruglyak, Howard Hughes Medical Institute and Fred Hutchinson, reported in today's (Sept. 8) issue of the journal Public Library of Science - Biology, that the African-American population fits best the expansion model and the European-American population fits best the bottleneck model.

After the demographic models suggested the structure of the populations, the researchers looked at the possible areas where natural selection occurred. They looked at 132 genes from 24 African Americans and 23 European Americans. These genes were originally sequenced because they all have something to do with the inflammation immune response. Some of these genes are known to affect risk of genetic disease, but most are not associated with genetic diseases.

"It is very difficult to see a compelling signature of natural selection if we look at only one gene, but if we look at many related genes, it becomes easier to identify," says Shriver. "We found a cluster of four genes that appear to be heavily selected." This 115-kilobase region shows many signs of a recent selective sweep, but only in the European-American population. Recent for geneticists is something like 20 to 25,000 years ago. One hypothesis of human population movement suggests that a small number of humans moved out of Africa and populated the rest of the world. This scenario fits the idea of a European population that had a bottleneck - the small population leaving Africa.

This small population was also exposed to a large amount of new environmental pressures, while the African population may already have been adapted to its African environment at these particular genes. Shriver emphasized that, "It is notable that there are a number of genes where African populations are known to have undergone recent natural selection and so it is a hasty generalization to conclude that more changes are found out Africa.

"The European-American population was challenged by more new things in its environment," says Shriver. "And this challenge is reflected in adaptation to new parasites or new environmental factors."

The researchers cannot identify an individual gene in the cluster of four that was selected, but one of the genes, TRPV6 might be involved in susceptibility to aggressive prostate cancer and since there is a large difference in the prevalence of prostate cancer between the European- and African-American populations, TRPV6 may be the selected gene. TRPV6 and TRPV5 are involved in calcium absorption. Northern Europeans have been nearly universally selected for a tolerance for milk, while African and other populations have a high degree of lactose intolerance. The ability to drink large amounts of milk has been strongly selected in Northern Europeans since about 9,000 years ago when dairy-producing animals were domesticated. The researchers suggest that perhaps a need for more calcium because of changes in TRPV6 and TRPV5 pushed the selection of milk tolerance.

Tracking natural selection does not just illuminate adaptation to new dietary possibilities like milk drinking but can also help in mapping genes underlying complex human diseases.
-end-


Penn State

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.